Down 50%, Is Chewy Stock a Buy on the Latest Dip?

Chewy reported revenue growth of more than 7% year over year to $3.33B, adjusted EPS of $0.36 (+9% YoY), and adjusted EBITDA of $226.7M (+7% YoY), although results included roughly $15M of non-recurring benefits and shares fell 11% after the release. EBITDA margin expanded 90bps to 6.8%, while Autoship sales rose more than 9% to $2.82B and represented nearly 85% of sales. Management raised full-year revenue guidance to $13.46B-$13.57B and adjusted EBITDA-margin guidance to 6.7%-6.8%, but expects continued consumer pressure and sequential gross-margin decline in Q3.

Analysis

CHWY’s valuation support is real only if its recurring-revenue mix converts into clean margin expansion. The key issue is not demand durability but earnings quality: one-time/re-timed commercial items obscured the underlying gross-margin trajectory, while SG&A still grew faster than revenue. A lower-multiple outcome is plausible if investors conclude that fulfillment automation savings are being reinvested into retention rather than dropping to EBITDA.

Near term, the stock needs evidence that the redesigned membership program lifts order frequency and retention without adding subsidy pressure. The most relevant 1-3 month catalyst is a clean quarterly print showing stable core gross margin, sequential SG&A leverage, and resilient active-customer growth; revenue guidance alone will not reset the multiple. Discretionary pet weakness also creates a competitive opening for mass merchants WMT and TGT, which can bundle pet purchases with essential baskets and use loyalty programs to absorb promotions.

The 6-18 month upside is healthcare mix: veterinary, pharmacy and insurance-adjacent engagement can raise wallet share and reduce switching versus commodity food retailing. But that thesis requires proof of attractive unit economics; care delivery is capital- and labor-intensive, so rapid expansion could dilute returns even as revenue accelerates. Consensus appears too focused on the low headline P/E and insufficiently focused on whether normalized EBITDA can sustainably exceed the guided range without vendor economics or promotional restraint doing the work.

Key Decisions for Investors

• Watch, do not add aggressively before the next earnings release: require core gross-margin stability and SG&A leverage excluding commercial timing items. A guidance increase paired with another low-quality beat would falsify the operating-leverage thesis.
• For a 3-6 month tactical position, initiate a small long CHWY only if post-earnings weakness holds and management demonstrates normalized EBITDA-margin expansion; target a rerating toward a mid-teens forward P/E, with a stop on a material cut to full-year EBITDA-margin guidance.
• Express the competitive-risk hedge through a CHWY/WMT relative-value pair: long CHWY versus short WMT only after evidence that membership/healthcare initiatives improve retention, since WMT is better positioned if pet spending remains promotional and discretionary categories deteriorate.
• Track veterinary and pharmacy disclosure at the next two reports: accelerating healthcare revenue without worsening consolidated gross margin supports a 12-18 month long; rising capital intensity, clinician costs, or fulfillment expense would argue against treating healthcare as a higher-margin catalyst.